Trial Profile
A Phase I, Open-Label, Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2020
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 16 Nov 2020 Results published in the European Journal of Clinical Pharmacology
- 08 May 2010 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 08 May 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.